Medical experts at Endoverse dispel the myths surrounding hemp seed oil and CBD.
According to an Alphagreen report, CBD usage is increasing and public interest in CBD is at an all time high.
But questions have been raised about proper intake, with the report finding 55 percent of people struggle to find high quality information to support their purchasing decisions.
The UK’s first organisation dedicated to the study of Endocannabinology, Endoverse is on a mission to simplify food supplement messaging and debunk myths surrounding hemp seed oil and CBD.
The team believes that consuming the correct ratio of fatty acids is key to maintaining good health – and with hemp seed oil packed full of omega 3 and 6 – they are frequently asked to explain the differences between the oil and CBD.
Dr Kristina Ranna, chief medical officer at Endoverse said: “If you search the internet, you will find a lot of ‘expert answers’ highlighting the importance of hemp seed oil as a good source of omega fatty acids, but in general they claim it’s not interacting with the ECS. This is completely wrong.
“Endocannabinoids like anandamide and 2-AG, as well as a broad family of other endocannabinoids, are produced from fatty acids. In recent times, fats have been viewed as a threat to health despite their key role in our bodies.
“The ECS system was only identified in the early 1990s and is key to maintaining homeostasis – metabolic balance. This balance is related to many external and internal factors. One of the key roles for ECS balance is interplay between fatty acid derived endocannabinoids.”
Although Endoverse experts are keen to stress CBD can be a useful supplement to achieve ECS balance, the real game-changing oils are actually those full of fatty acids.
Dr Ranna continues: “At Endoverse, we see the role of hemp seed oil, as well as some other plant derived cold-pressed oils, such as walnut, as superior and more important for the Endocannabinoid balance itself, than CBD oil.
“This doesn’t mean that we are not recommending CBD. CBD as a negative allosteric modulator of CB1 receptors has the capability to down-regulate their activity, and the combination of hemp seed oil and CBD is great.”
Hemp seed oil comes from the seeds of Cannabis sativa plants and contains only traces of CBD and other cannabinoids.
It is made by cleaning and pressing the seeds and is green in colour with a nutty flavour. CBD oil is produced from the leaves, stalks and flowers of the plant.
Hemp seed oil contains polyunsaturated fatty acids – omega 6 and omega 3 – which are not produced by the body and must be obtained through diet.
ECS balance is achieved through lifestyle modifications including attaining an ideal ratio of omega 3, omega 6 and other fatty acids. Applying these modifications correctly – and with the assistance of an endocannabinologist – could be the key to improving many common health conditions, such as obesity.
Dr Ranna explains: “Despite the popularity of clinical endocannabinoid system deficiency syndrome, we know that the real problem of Western societies is an overactivated endocannabinoid system, which long-term induces Metabolic syndrome. This syndrome is characterised by increased Body Mass Index, increased blood sugar levels and blood pressure and a disturbed serum level of cholesterol and triglycerides.
“Consequences of metabolic syndrome are diabetes, cardiovascular disorders, stroke and a risk factor for cancer. There is also a clear link between metabolic syndrome and Covid-19 severity.”
To achieve benefits from hemp seed oil, it is important to use the correct amount – Dr Ranna recommends 10g to cover your daily recommended intake of omega 3 fatty acids, half of daily recommended omega 6 intake, and will provide you with 1g of omega 9.
Dr Ranna added: “Endoverse is at an exciting stage, we have completed our first Endocannabinologist training course and are working on a series of initiatives including webinars and retreats.
“Our next training course starts in June and we also want to work closely with CBD companies and those interested in the ECS to ensure proper education and public messages.”
Anyone who wants to learn more can contact Endoverse at firstname.lastname@example.org
Cystic fibrosis and cannabis – new survey highlights lack of education
Almost three quarters of healthcare providers felt unprepared to answer patient’s questions about cannabis
A new survey has revealed that how healthcare professionals approach cannabis use in cystic fibrosis (CF) patients varies across the US.
The approach to cannabis use assessment, documentation, and education across care centres is “variable”, according to the study, published in the journal Paediatric Pulmonology.
Out of nearly 300 healthcare professionals working with CF patients across the US, almost three quarters (72 percent) felt “not at all” prepared to answer patient’s questions about cannabis and CBD.
Nearly half assessed patients’ cannabis use on occasion, with 41 percent rarely or never asking about it, and 15.4 percent always assessing its use.
What is cystic fibrosis?
CF is a progressive, genetic disease that affects the lungs, digestive system, pancreas, and other organs.
It causes persistent lung infections and can affect the patient’s ability to breathe over time.
CBD has gained increasing interest as a potential treatment for several health conditions.
But the role of cannabis and CBD in healthcare “remains relatively controversial” with a lack of safety and efficacy data in specific chronic diseases, such as CF, according to researchers.
Cannabis is commonly consumed through inhalation, such as smoking or vaping, a method of administration not recommended to CF sufferers.
The study aims to help open the dialogue around cannabis use in people living with cystic fibrosis.
A cross-sectional survey of 282 healthcare professionals working with CF patients, analysed participants’ awareness of current cannabis laws in their state, as well as prescribing practices for medical cannabis, documentation and assessment.
They were also asked what indications they believe cannabis and CBD could be beneficial for, with appetite, pain, and nausea reported as the top three reasons for use.
The authors called for more care teams and patient/caregiver education materials about cannabis, CBD and CF.
“As research interest in cannabis and its chemical components continues to advance and as accessibility of cannabis and CBD widens, it is prudent to include cystic fibrosis in the conversation,” they stated.
Access the full study here
Why are cannabis medicines helpful for fibromyalgia?
Dr Anthony Ordman explains why cannabis medicines are so useful in the treatment of fibromyalgia
Leading UK pain consultant, Dr Anthony Ordman, explains why cannabis medicines are so useful in the treatment of fibromyalgia.
Over the years at his ground-breaking pain medicine clinic at the Royal Free Hospital, Dr Ordman has treated countless fibromyalgia patients.
He is a former president of the pain division of the Royal Society of Medicine and is now hon. medical director at Integro Clinics, where he prescribes cannabis based medicines (CMBP’s). He explains why patients living with the condition might wish to explore medical cannabis.
Whilst here is no one conventional medicine to treat fibromyalgia, often, anti-depressants and nerve pain medicine are tried.
Although these medicines can sometimes help, they often have nasty side effects, which can leave patients suffering more. Cannabis medicines can offer a potentially extremely effective treatment as they re-balance and regulate the human body’s natural endocannabinoid system (ECS) without leaving a patient with debilitating side effects.
I have observed that many fibromyalgia patients are extremely emotionally alert and simply cannot allow themselves to relax at night. This can be a result of persistent stress or traumatic life events. The conventional drugs that are available do not penetrate the bodies spinal cord and central nervous system, which cannabis medicines can.
It is much better to use CMBP’s because they can reduce muscle tension mechanisms in the central nervous system which allows the patient to sleep better and recharge emotionally. If you have had a better night’s sleep, pain is likely to be less the next day.
Many of my patients have been self-medicating for years before coming to see me. I cannot stress enough how big a difference there is between medicinal cannabis and street cannabis. The effectiveness of medicinal cannabis compared to black market product is immeasurable. The production of medicinal cannabis is done under very strict conditions and measure precisely to find the most suitable dosage for each condition.
If you are really suffering from your fibromyalgia symptoms and the conventional medicines you have been prescribed are not helping you, I would seriously advise you to consider trying medical cannabis.
I am increasingly aware that we are only just starting to understand the significant effects that cannabis medicines can have on people’s pain.
The team at Integro Clinics, where I practice, is completely patient centric and we are heavily focussed on finding the right dose foe each patient which we monitor regularly and adapt if necessary. We also have a specialist practise nurse, Sophie, who is available for any advice you may need.
If you would like further information or to speak to Dr Anthony Ordman or specialist nurse, Sophie Hayes, please contact Integro Clinics via email Contact@integroclinics.com or at www.integroclinics.com
Follow them on Twitter @clinicsintegro
Integro Medical Clinics Ltd always recommend remaining under the care and treatment of your GP and specialist for your condition, while using cannabis-based medicines, and the Integro clinical team would always prefer to work in collaboration with them.
Alzheimer’s disease: Could cannabis be an effective treatment?
The number of people living with Alzheimer’s disease is expected to triple by 2050
The number of people living with Alzheimer’s disease is expected to triple by 2050 – but ongoing studies suggest cannabinoids may be an effective treatment.
Alzheimer’s disease is a neurodegenerative disorder defined by a decline in cognitive and functional abilities, which is thought to affect 35 million people worldwide.
Realm of Caring (RoC), a non-profit organisation that focuses on education and access to cannabinoid therapy, is a frontrunner in researching the effects of cannabis on conditions such as Alzheimer’s, as well as discussing options with patients considering cannabis treatment.
RoC recently reported that to date, six clinical trials, in which patients were given THC, have found that the cannabinoid can ease aggression and agitation, two of the defining symptoms associated with the condition.
Alzheimer’s is characterised by the frequent occurrence of neuropsychiatric symptoms (NPS), including depression, irritability, aggression, and agitation. These symptoms have been reported to occur in 98 percent of patients, with agitation present in 55 percent of this population at some point in the illness.
The most distinguishing features of agitation include excessive fidgeting, restlessness, pacing, shouting, screaming, and motor activities associated with anxiety, such as hand wringing as reported by RoC.
Common symptoms of aggression include shouting and verbal insults, hitting, biting others, and throwing objects.
The first line of treatment involves non-pharmacological interventions such as person-centred care, structured social interaction, and music therapy. However, due to the complexity of the disease it is unlikely that any one drug or intervention will treat it fully.
Some researchers have suggested that the adverse effects from prescribed medications offset the potential advantages, as efficacy has proven to be limited.
Researchers on behalf of RoC believe alternative treatments should be available.
“Cannabis research for Alzheimer’s is critical because this disease affects tens of millions of individuals globally, and to date, there is no curative treatment available,” commented Nicolas Schlienz, PhD, research director at RoC.
“Current pharmacological therapies do not reverse the progression, but the human endocannabinoid system (ECS) has emerged as a promising therapeutic avenue due to its ability to modulate the causes and effects of the disease.
“Research has shown that modulation and regulation of the ECS through cannabinoids such as delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD) offer neuroprotective, anti-inflammatory and antioxidant benefits as well as the ability to reduce excitotoxicity and oxidative stress.”
He added: “Further research is warranted, given the body of preclinical evidence that points to cannabis extracts as being beneficial for slowing the progression of Alzheimer’s and alleviating corresponding symptoms.
“Of the research available, studies suggest CBD as a favourable treatment strategy for neurodegenerative diseases such as Alzheimer’s in providing symptom relief and potential slowing of disease progression.”
With the numbers of patients being diagnosed with the condition rising, more and more individuals are reaching out to RoC for advice and guidance around using cannabis treatment for Alzheimer’s and other neurodegenerative conditions.
“As the stigma lessens, research begins to acknowledge the therapeutic value of cannabis,” Schlienz added.
“At RoC there is one-on-one support for any individual wishing to discover more information about cannabinoid therapy. Our care specialists help to navigate the many options available.
“They can speak in detail about dosing guidelines and how to find a quality product, as well as offer resources such as research articles and guidance on how to talk with your doctor about cannabinoid therapy.”
RoC always recommends that a licensed healthcare provider should be consulted prior to beginning cannabinoid therapy.
Access support from Realm of Caring here
Introducing our new B2B title
- Cystic fibrosis and cannabis – new survey highlights lack of education
- Why are cannabis medicines helpful for fibromyalgia?
- Alzheimer’s disease: Could cannabis be an effective treatment?
- Five ways to practice mindfulness with CBD
- Medical cannabis cultivation gets green light in Guernsey
- Cannabis and motherhood: “My children get to see me smile more”
News1 year ago
NHS lines up cannabis medicine manufacturing
News8 months ago
Community extends support to cannabis icon Rick Simpson
Case Studies1 year ago
CBD oil and fibromyalgia – a case study
News10 months ago
Cancer survivor claims cannabis oil helped her beat brain tumour
Insight10 months ago
I’ve gone from a wheelchair to walking thanks to cannabis
Feature1 year ago
Medical cannabis could help long-term effects of COVID-19, says David Nutt
News7 months ago
UK grants second licence to grow high-THC medical cannabis
Industry6 months ago
“Game changer” for the sector: First cannabis company expected to list on LSE next month